Publicaciones en las que colabora con Ana Martínez (9)

2016

  1. Small GSK-3 Inhibitor shows efficacy in a motor neuron disease murine model modulating autophagy

    PLoS ONE, Vol. 11, Núm. 9

2015

  1. Analysis of β-N-methylamino-l-alanine (L-BMAA) neurotoxicity in rat cerebellum

    NeuroToxicology, Vol. 48, pp. 192-205

  2. Morphometric and neurochemical alterations found in l-BMAA treated rats

    Environmental Toxicology and Pharmacology, Vol. 39, Núm. 3, pp. 1232-1245

2012

  1. Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals

    American Journal of Physiology - Endocrinology and Metabolism, Vol. 302, Núm. 7

2006

  1. TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors

    Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development (John Wiley & Sons, Inc.), pp. 257-280

2005

  1. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor γ activation

    Journal of Biological Chemistry, Vol. 280, Núm. 22, pp. 21453-21462

2004

  1. GSK-3 inhibitors: Discoveries and developments

    Current Medicinal Chemistry, Vol. 11, Núm. 6, pp. 755-763

2002

  1. First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

    Journal of Medicinal Chemistry, Vol. 45, Núm. 6, pp. 1292-1299

  2. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation

    Medicinal Research Reviews, Vol. 22, Núm. 4, pp. 373-384